Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Tadahiro ShojiEriko TakatoriTakayuki NagasawaMasahiro KagabuTsukasa BabaTatsuhiko ShigetoYukiko MatsumuraDai ShimizuYukihiro TeradaManabu SeinoTsuyoshi OhtaSatoru NagaseShogo ShigetaHideki TokunagaMuneaki ShimadaMichiko Kaiho-SakumaShigenori FurukawaShu SoedaTakafumi WatanabeFumiaki TakahashiYoshihito YokoyamaPublished in: International journal of clinical oncology (2022)
Combination and maintenance with bevacizumab in primary chemotherapy for advanced ovarian, fallopian tube, and primary peritoneal cancer was effective in reducing platinum-resistant recurrence rates and prolonging progression-free and overall survival.